Cycle on Jun 15, 2026

I will list the open threads for the topic to see if there are any specific questions, investigations, or watches that need to be addressed in this cycle.

I will run a web search to check for recent news on Zepzelca (lurbinectedin), Tavneos (avacopan), and other recent major clinical trial or regulatory updates in the health and science space around June 2026.

This is a critical development. The Phase 3 LAGOON trial results for Zepzelca (lurbinectedin) were announced just days ago (around June 12, 2026). Let's fetch the Fierce Pharma article to see the details of this failure and its regulatory implications. I'll also do a search on Tavneos (avacopan) to see if there are updates ahead of its June 29, 2026 hearing/public docket close. Let's do both. First, let's fetch the Fierce Pharma article on Zepzelca.

This is a very clear and substantial update on the thread `019ec855-c507-7a87-9478-04ec177c54da` (FDA regulatory decision on Zepzelca's second-line SCLC indication). The watch trigger says: "Fires when the FDA or Jazz announces a regulatory decision, label update, or withdrawal of the second-line SCLC indication for Zepzelca." Wait, the watch itself is on the *regulatory decision*, but the trial results have just been released and Jazz announced they have shared the results with the FDA and will discuss next steps. The watch itself might not be fully resolved until the FDA actually makes a decision on the indication (e.g. withdrawal or label update), but let's see if we should record an event. Wait, let's read the watch description: "Monitor the FDA's regulatory decision or next steps regarding Jazz/PharmaMar's Zepzelca (lurbinectedin) accelerated approval for second-line SCLC following the Phase 3 LAGOON trial failure." Wait, the trial failure *just* happened on June 12, 2026! This is a brand new development. Let's record this as a finding and see if we can resolve or update any threads or watches. Let's first search to see if there is any other major news in the last few days in health/science, particularly on Tavneos (avacopan). Let's do a search on Tavneos.

Excellent. Let's fetch the MedCity News or Fierce Pharma article on Tavneos to get the detailed findings of Amgen's recent submission and the independent review. Let's fetch the MedCity News article first.

Let's fetch the Fierce Pharma article on Tavneos as well to ensure we have any additional details.

These are excellent details. Let's look at other threads and watches. Let's see: - sBLA submission for Zynlonta plus rituximab in r/r DLBCL (ADC Therapeutics) - NMPA regulatory decision on IBI343 (world's first CLDN18.2 ADC) - Global Phase 3 trial readouts for ivonescimab (HARMONi studies) - Clinical trial initiation/readout for fast-tracked Bundibugyo Ebola vaccines - FDA regulatory filing/decision on Eli Lilly's Foundayo in Type 2 diabetes - Belite Bio's NDA for tinlarebant in Stargardt disease type 1 - Disc Medicine bitopertin Phase 3 APOLLO trial readout and FDA CRL decision - Sanofi riliprubart CIDP VITALIZE trial - Dianthus Therapeutics claseprubart Phase 3 CAPTIVATE trial - Eli Lilly SURPASS T1D-1 Phase 3 trial - DIOSynVax AI-designed universal Sarbeco vaccine Phase II - Alterity Therapeutics ATH434 Phase 3 MSA - Pfizer berobenatide Phase 3 obesity - VGA039 in von Willebrand disease - ISS Russian Zvezda module air leaks - Roche giredestrant HR+ early-stage breast cancer FDA regulatory decision - Cogent Biosciences bezuclastinib in GIST FDA regulatory decision - Moderna Phase 3 mRNA-1018 bird flu vaccine trial Let's do a search on recent drug approvals or major Phase 3 trials in June 2026. Let's search for "FDA approval" with freshness "week" or "month" to see if there are any other massive approvals or regulatory changes in the last week or two. Let's also search for some of the watch entities (e.g. Belite Bio tinlarebant, ADC Therapeutics Zynlonta, Dianthus Therapeutics, etc.). Let's start with a broad search for recent FDA approvals and drug news.

This is incredible! 1. "The FDA approves Sanofi's Tzield for type 1 diabetes, now available for children aged 8-17 recently diagnosed with stage 3." This was on June 12-15, 2026. This is an expansion of Tzield (teplizumab-mzwv) to pediatric patients with Stage 3 T1D! Let's fetch the details of this. Wait, let's look at our watch list: `019ec32d-357a-793f-b934-70957f5a30f5`: "Monitor the Phase 3 BETA-PRESERVE (NCT07088068) confirmatory study for Sanofi's Tzield (teplizumab-mzwv) in newly diagnosed Stage 3 Type 1 diabetes to verify clinical benefit following its accelerated approval." Wait, does this FDA expansion of Tzield represent the readout of the BETA-PRESERVE trial, or is it a different trial? Let's check! 2. "FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation..." on June 12, 2026. 3. "FDA approved belzutifan (Welireg) in combination with pembrolizumab (Keytruda)..." on June 12, 2026. 4. "Precigen (NASDAQ:PGEN) received FDA orphan drug exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) for adult recurrent respiratory papillomatosis (RRP),..." wait, did Papzimeos get FDA approval recently? Let's check! Let's do a search on Tzield's expanded approval for pediatric Stage 3 Type 1 Diabetes and see if it was based on the BETA-PRESERVE trial or another trial (like PROTECT or something else). Let's search for "Tzield FDA pediatric Stage 3 Type 1 Diabetes June 2026".

This is a huge development! The FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) on June 12, 2026, for pediatric patients (aged 8-17) with newly diagnosed Stage 3 Type 1 Diabetes, based on the Phase 3 PROTECT trial data! Wait, let's fetch the BioSpace article on Tzield's accelerated approval and the CNPV (Commissioner's National Priority Voucher) details, as well as the FDA's main announcement. First, let's fetch the BioSpace article.

This is an incredible story! It links several pieces: - The FDA's accelerated approval of Sanofi's Tzield (teplizumab-mzwv) on Friday, June 12, 2026, for pediatric patients (ages 8-17) who have recently been diagnosed with stage 3 type 1 diabetes. - This was based on the Phase 3 PROTECT trial data. - The approval was granted under the accelerated pathway and the continued approval depends on the Phase 3 BETA-PRESERVE confirmatory study, which is currently recruiting and expected to read out in 2028 (which matches our watch `019ec32d-357a-793f-b934-70957f5a30f5`). - The approval comes after a major internal battle at the FDA. Tracy Beth Høeg, the former acting director of CDER, reportedly disagreed with agency staff who wanted to approve the drug, arguing that Tzield's benefits did not outweigh its risks in this population. Sanofi had even requested to withdraw the drug from the CNPV (Commissioner's National Priority Voucher) program in May after Høeg got involved. However, Høeg was fired in May 2026, and Michael Davis became the acting CDER head, leading to the accelerated approval on June 12, 2026. Let's check if there are other threads or watches that have updates. Wait, let's search for "Belite Bio tinlarebant" to see if there is any update on its NDA submission or acceptance. Belite Bio submitted its NDA around June 2026 or late May 2026. The watch `019ec55-8c35-71a4-b33b-90db344bf45d` has a fire date of August 11, 2026, so it might not have fired yet. Let's do a search to see if there are any updates.

This is fantastic! On June 12, 2026, Belite Bio completed its rolling NDA submission to the FDA for tinlarebant in Stargardt disease type 1. This marks the completion of the submission, which triggers the 60-day filing review period where the FDA decides whether to accept the NDA for filing and assigns a PDUFA date. Let's fetch the Globe and Mail or Business Insider press release to get the precise details of this submission. Let's fetch the Globe and Mail article.

This is a great update. Belite Bio completed its rolling NDA submission on June 12, 2026. This starts the 60-day filing review period, which means we can record an event for our watch `019ec55-8c35-71a4-b33b-90db344bf45d`. Wait, the watch trigger is: "Fires when the FDA decides whether to accept the NDA for filing (expected around early August 2026, 60 days post-submission)." So the watch *has not yet resolved* because the FDA has not yet accepted the NDA for filing, but we can write a note about this completed submission and update the watch status if needed, or keep the watch open since it's expected in early August 2026. Let's check if there are other updates on the watches. What about `019e9f1e-f092-7114-960b-1c3b5c994320` (Moderna Phase 3 mRNA-1018 bird flu vaccine trial)? Let's search for "Moderna mRNA-1018 Phase 3 bird flu vaccine trial" or "Moderna bird flu vaccine trial results". Let's do a search.

Let's try a broader search for "Moderna bird flu vaccine" or "Moderna mRNA-1018".

Interesting! Let's check the MSN article about "Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma" to see what's happening with H5N1 bird flu policy and trials. Let's fetch the MSN article. Wait, let's also fetch the Medical Economics article or similar. First, let's search specifically for the MSN article's URL or title. Let's do a search to find the MSN source or another source on this.

Let's fetch this MSN article. It seems very relevant to the bird flu outbreak / public health / CDC policy. Let's see if we can fetch it.

This is fascinating! The CDC has deactivated/ended its emergency response to the H5N1 bird flu outbreak. This is a major public health policy shift. Let's record this as a finding under a new or existing slug, but let's check if there is an existing slug. Looking at the "Relevant prior findings for this topic", there doesn't seem to be a specific slug for bird flu, although we have a watch `019e9f1e-f092-7114-960b-1c3b5c994320`: "Monitor topline safety and immunogenicity readouts from Moderna's Phase 3 trial of mRNA-1018 (enrolling ~4,000 healthy adults in the US and UK)." Let's see if the trial is still ongoing. The article mentions that "earlier this year, HHS scrapped a $766 million deal with Moderna for developing mRNA bird flu vaccines... The U.S. reported its first human death from H5N1 in Louisiana and awarded $306 million for avian flu response, including $176 million to Moderna for its mRNA-1018 vaccine candidate." Wait, the article says the CDC deactivated its response "last week" (which would be early June 2026) and will now track bird flu alongside seasonal influenza, updating human monitoring monthly. Animal transmission data will no longer be published. Let's check if there are other major healthcare/science updates from this week. Let's look at the watch list again: - sBLA submission for Zynlonta plus rituximab in r/r DLBCL (ADC Therapeutics): let's search for "Zynlonta sBLA ADC Therapeutics 2026". - NMPA regulatory decision on IBI343 (world's first CLDN18.2 ADC): let's search for "IBI343 NMPA Innovent June 2026" or "Innovent Biologics CLDN18.2". - Global Phase 3 trial readouts for ivonescimab (HARMONi studies): let's search for "ivonescimab HARMONi June 2026" or "ivonescimab overall survival". - Clinical trial initiation/readout for fast-tracked Bundibugyo Ebola vaccines: let's search for "Bundibugyo Ebola vaccine trial 2026". - Eli Lilly's Foundayo: let's search for "Foundayo Eli Lilly orforglipron June 2026". - Cogent Biosciences bezuclastinib in GIST: let's search for "bezuclastinib Cogent June 2026" or "bezuclastinib GIST". - Roche giredestrant: let's search for "giredestrant FDA priority review adjuvant breast cancer June 2026". Let's run some searches to see if there are any fresh updates on these. Let's start with Zynlonta and IBI343.

Wait, let's search for "ADC Therapeutics Zynlonta sBLA LOTIS-5" on the web to see what's happening. Or "ADC Therapeutics Zynlonta FDA". Let's do a search.

This is a major and highly relevant development! On June 3, 2026, ADC Therapeutics announced topline results from the Phase 3 LOTIS-5 trial of Zynlonta (loncastuximab tesirine) in combination with rituximab in r/r DLBCL. The stock plunged 53% because of safety concerns (elevated serious and Grade 5 adverse events / deaths), despite positive PFS results! Let's fetch the BioSpace press release or the Seeking Alpha article to get the details of this. This directly relates to the watch thread `019e9f1e-b37e-771d-884b-b07383d792b7` ("Monitor ADC Therapeutics' planned sBLA submission in Q4 2026 following the pre-sBLA meeting with the FDA in August 2026 to see if safety concerns (13.2% fatal TEAEs in LOTIS-5) delay or alter the regulatory path."). Let's fetch the BioSpace article first to read the exact details of the trial results and safety concerns. This is perfect for a new finding or watch event!

Ah, the web_search budget is spent. No problem, we have plenty of highly detailed, primary-source, and extremely relevant developments to write up into notes and resolve/update our watches and threads! Let's review what we have: 1. **Zepzelca (Lurbinectedin) Confirmatory Failure in Relapsed SCLC (Phase 3 LAGOON)**: - On June 12, 2026, Jazz Pharmaceuticals and PharmaMar announced that the Phase 3 LAGOON confirmatory trial for Zepzelca in second-line small cell lung cancer (SCLC) failed to meet its primary endpoint of overall survival (OS). - Zepzelca monotherapy actually performed worse than the control arm (median OS of 8.7 months vs 10.7 months, HR representing a 19% higher risk of death). - The Zepzelca-irinotecan combination showed a numerical but statistically non-significant 9.8% improvement in OS. - This failure is a massive blow, as it was intended to confirm the accelerated approval granted in 2020. This follows a previous Phase 3 trial failure (ATLANTIS) which the FDA allowed to pass because of dosing differences and unmet need. Now, with a second confirmatory failure at approved dosing, Zepzelca's second-line indication is in serious jeopardy, especially with competing therapies like Amgen's Imdelltra gaining traction. - We will write a note on this and update the watch thread `019ec855-c507-7a87-9478-04ec177c54da` (which we should keep open since the *regulatory decision* by the FDA is still pending, but we should record an event or update the thread). Wait, can we record an event on it? The thread kind is `watch` with a trigger: "Fires when the FDA or Jazz announces a regulatory decision, label update, or withdrawal of the second-line SCLC indication for Zepzelca." Since a regulatory decision/withdrawal has NOT happened yet (they are just discussing it with the FDA), we shouldn't resolve it, but we can write a note about the trial failure and keep the watch open. Wait, let's look at the watch list: can we record an event? Yes, let's record an event with `resolves: false` (since it's ongoing or not yet fully resolved, but wait, the watch cardinality is `one_shot` so if we record an event with `resolves: false` it keeps it open, or we can just write the note). Let's record an event with `resolves: false` to show the trial failed and the company is meeting with the FDA. 2. **Amgen Tavneos (Avacopan) FDA Withdrawal Defense & Independent DCRI Review**: - Amgen has formally requested an FDA hearing to fight the FDA CDER's proposal to withdraw approval of Tavneos (avacopan) for ANCA-associated vasculitis. - Amgen's defense will include an independent re-evaluation of the pivotal Phase 3 ADVOCATE trial data, commissioned from the Duke Clinical Research Institute (DCRI). This analysis, along with other supporting evidence, is due by June 29, 2026, which is also when the FDA public comment period closes. - The FDA's push to withdraw the drug stems from allegations of clinical trial data manipulation by previous owner ChemoCentryx (which Amgen acquired for $3.7B in 2022) revealed in shareholder litigation, as well as mounting safety concerns (76 cases of drug-induced liver injury, including 8 deaths). - We have watch `019ec855-5381-7936-a3b6-a40d207e679d` (Amgen Tavneos FDA hearing submission and public docket close) with a fire date of June 29, 2026. This watch is set to fire when Amgen submits its evidence and the public docket closes on June 29, 2026. Since today is June 15, 2026, the submission hasn't fully occurred yet, but Amgen has officially requested the hearing and announced the DCRI review. We can write a note to document this development and keep the watch open. 3. **Sanofi Tzield (Teplizumab-mzwv) Expanded FDA Accelerated Approval for Pediatric Stage 3 T1D**: - On June 12, 2026, the FDA granted accelerated approval to Sanofi’s Tzield to slow the decline of endogenous insulin production in pediatric patients ages 8 to 17 with newly diagnosed Stage 3 Type 1 Diabetes. - This approval is based on the Phase 3 PROTECT trial, which showed that Tzield significantly preserved C-peptide levels (a surrogate marker for insulin secretion) compared to placebo. - The approval was marked by intense internal controversy at the FDA. Tracy Beth Høeg, then-acting director of CDER, reportedly opposed the approval, arguing that the benefits did not outweigh the risks. Sanofi even requested to withdraw Tzield from the Commissioner's National Priority Voucher (CNPV) program in May after Høeg's intervention. However, Høeg was fired in May 2026 and replaced by Michael Davis on an acting basis, paving the way for the June 12 approval. - Continued approval is contingent on verifying clinical benefit in the ongoing Phase 3 BETA-PRESERVE trial (expected to read out in 2028). - This directly relates to watch `019ec32d-357a-793f-b934-70957f5a30f5` (Sanofi Tzield Phase 3 BETA-PRESERVE confirmatory trial in Stage 3 T1D). The watch is to monitor the BETA-PRESERVE trial, which is currently recruiting. We can write a note about this label expansion and keep the watch open. 4. **Belite Bio Tinlarebant Rolling NDA Submission Completed**: - On June 12, 2026, Belite Bio completed its rolling NDA submission to the FDA for tinlarebant (LBS-008) for the treatment of Stargardt disease type 1 (STGD1). - This completion starts the FDA's 60-day filing review period. If accepted, the FDA will assign a PDUFA target action date (expected around August 2026). - This directly relates to watch `019ec855-8c35-71a4-b33b-90db344bf45d` (FDA filing acceptance and PDUFA date for Belite Bio's tinlarebant). The watch trigger is "Fires when the FDA decides whether to accept the NDA for filing (expected around early August 2026, 60 days post-submission)." Since the submission was just completed on June 12, the 60-day clock has started, and we should keep the watch open until August. We will write a note on this. 5. **ADC Therapeutics Zynlonta (Loncastuximab Tesirine) Phase 3 LOTIS-5 Results and Safety Concerns**: - On June 3, 2026, ADC Therapeutics announced topline results from the Phase 3 LOTIS-5 confirmatory trial of Zynlonta plus rituximab in relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). - While the trial met its primary endpoint of progression-free survival (PFS) with statistical significance (median PFS of 6.1 months vs 4.7 months, HR = 0.73, p = 0.008), it revealed severe safety concerns. - Grade 5 (fatal) treatment-emergent adverse events (TEAEs) were significantly higher in the Zynlonta plus rituximab arm (13.2% or 27 patients) compared to the control R-GemOx arm (4.6% or 9 patients). The majority of these fatal events occurred in patients aged 75 or older. - Following the announcement, the stock plummeted over 53%. - Despite these safety concerns, ADC Therapeutics plans to conduct a pre-sBLA meeting with the FDA in August 2026 and submit a supplemental BLA in Q4 2026. - This directly relates to watch `019e9f1e-b37e-771d-884b-b07383d792b7` ("Monitor ADC Therapeutics' planned sBLA submission in Q4 2026 following the pre-sBLA meeting with the FDA in August 2026 to see if safety concerns (13.2% fatal TEAEs in LOTIS-5) delay or alter the regulatory path."). We can write a note and keep this watch open. 6. **CDC Deactivates Emergency Response to H5N1 Bird Flu Outbreak**: - The U.S. Centers for Disease Control and Prevention (CDC) has ended its emergency response to the H5N1 bird flu outbreak. - The agency deactivated its response in June 2026 and will now monitor human cases of bird flu alongside seasonal influenza, transitioning to monthly human data updates. - Crucially, animal transmission data will no longer be published by the CDC, and affected states like California (which ended its emergency declaration in April) and Washington are scaling back their public health responses. - Public health experts have criticized the move, warning that "we are letting our guard down" and that the lack of surveillance will make it harder to spot the next outbreak. - This directly relates to the bird flu public health response and the tailwinds for pandemic-preparedness companies (like Moderna, whose $766 million deal with HHS was scrapped earlier this year, though its Phase 3 mRNA-1018 trial remains ongoing under watch `019e9f1e-f092-7114-960b-1c3b5c994320`). We will write a note on this. Let's check if there are any existing notes that we can update or if we should write new notes. Let's call `read_notes` to see what notes currently exist on this topic. This is a very important step to ensure we reuse slugs where appropriate!

Ah, let's see. This is wonderful! There are several existing notes that match our updates perfectly: - `zepzelca-phase3-lagoon-sclc-failure` (already exists!) - `amgen-tavneos-fda-scrutiny-withdrawal-dispute` (already exists!) - `belite-bio-tinlarebant-stargardt-disease-nda` (already exists!) - `sanofi-tzield-type1-diabetes` (already exists!) - `zynlonta-phase3-lotis5-dlbcl-safety-concerns` (already exists!) And we have a brand new development about the CDC ending its emergency response to the H5N1 bird flu outbreak. We can write a new note for that, perhaps with a slug like `cdc-ends-h5n1-bird-flu-emergency-response`. Let's carefully verify the guidelines for writing notes: - Use the SAME slug to update an existing note. - Name a slug for the DURABLE SUBJECT, never the transient story-of-the-day. - Carry 1-2 representative verbatim quotes, copied exactly, each kept with the link it came from. - Name and link the actual thing (the story, article, paper, or page) — not just "the discussion". - No YAML frontmatter — the title is the first `#` heading and the slug is the slug parameter. - Use wikilinks `[[slug]]` to link to other findings. Let's review the notes we need to write/update: 1. **Zepzelca (Lurbinectedin) Phase 3 LAGOON failure**: - Slug: `zepzelca-phase3-lagoon-sclc-failure` - Let's update this note with the newly announced results from June 12, 2026. - We will cite the Fierce Pharma article we fetched. - Let's extract verbatim quotes from the Fierce Pharma article: - "According to Jazz, Zepzelca monotherapy performed even worse than the control arm, with a 19% higher risk of death. Patients who got Zepzelca alone lived a median 8.7 months, versus 10.7 months for those in the control arm." - "Zepzelca-irinotecan showed a numerical, but marginal, overall survival benefit with a 9.8% improvement, which didn’t meet statistical significance, according to Jazz." - Let's write the note body. 2. **Amgen Tavneos (Avacopan) FDA hearing request and DCRI review**: - Slug: `amgen-tavneos-fda-scrutiny-withdrawal-dispute` - Let's update this note with the formal hearing request and the selection of the Duke Clinical Research Institute (DCRI) to lead the re-evaluation of the ADVOCATE trial data. - We will cite the MedCity News and Fierce Pharma articles we fetched. - Let's extract verbatim quotes: - From MedCity News: "The pharmaceutical company disclosed the independent review in a letter to the FDA requesting a hearing regarding the agency’s proposal to withdraw approval of the drug, Tavneos. ... The DCRI analysis and all other supporting documents in support of Amgen’s hearing request are due by June 29." - From Fierce Pharma: "In February, the California drugmaker brought on the Duke Clinical Research Institute (DCRI) to review data from the phase 3 Advocate study, according to a letter sent earlier this month by Amgen to the FDA." - Let's write the note body. 3. **Sanofi Tzield (Teplizumab) FDA Accelerated Approval & FDA CDER Internal Controversy**: - Slug: `sanofi-tzield-type1-diabetes` - Let's update this note with the accelerated approval on June 12, 2026, for pediatric patients (ages 8-17) with newly diagnosed Stage 3 Type 1 Diabetes, and the dramatic back-story of CDER internal disagreements leading to the firing of acting CDER director Tracy Beth Høeg and her replacement by Michael Davis. - We will cite the BioSpace article we fetched. - Let's extract verbatim quotes: - From BioSpace: "Tzield’s label expansion, granted Friday under the FDA’s accelerated pathway, extends the drug’s use to patients ages eight through 17 years who have recently been diagnosed with stage 3 type 1 diabetes... Sanofi has launched the Phase 3 BETA-PRESERVE trial to fulfill this requirement." - From BioSpace: "Acting Center for Drug Evaluation and Research Director Tracy Beth Høeg reportedly disagreed with staff who wanted to approve Sanofi’s type 1 diabetes drug. ... Høeg is no longer at the agency after being fired that same month. She has been succeeded by CDER deputy director Michael Davis..." - Let's write the note body. 4. **Belite Bio Tinlarebant Rolling NDA Completed**: - Slug: `belite-bio-tinlarebant-stargardt-disease-nda` - Let's update this note with the completion of the rolling NDA submission on June 12, 2026, triggering the 60-day FDA review period. - We will cite the Markets Insider press release we fetched. - Let's extract verbatim quotes: - From Markets Insider: "today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. ... The completed application will undergo the 60-day review period with the FDA, and if accepted, a Prescription Drug User Fee Act (PDUFA) target action date will be assigned." - Let's write the note body. 5. **ADC Therapeutics Zynlonta (Loncastuximab Tesirine) Phase 3 LOTIS-5 Safety Concerns**: - Slug: `zynlonta-phase3-lotis5-dlbcl-safety-concerns` - Let's update this note with the detailed LOTIS-5 Phase 3 confirmatory trial results announced on June 3, 2026, including the 13.2% vs 4.6% Grade 5 (fatal) TEAE imbalance, and the planned sBLA submission in Q4 2026. - We will cite the BioSpace press release we fetched. - Let's extract verbatim quotes: - From BioSpace: "A higher rate of Grade 5 TEAEs was observed in the ZYNLONTA plus rituximab arm (27 pts/13.2%) vs. R-GemOx (9 pts/4.6%). Of note, the majority of Grade 5 TEAEs in the test arm occurred in patients aged 75 years or older." - From BioSpace: "Based on these topline results from LOTIS-5, we look forward to discussing next steps for this combination of ZYNLONTA plus rituximab with the U.S. FDA... We intend to conduct a pre-sBLA meeting in August and are preparing for a planned sBLA submission in the fourth quarter of 2026." - Let's write the note body. 6. **CDC Ends H5N1 Bird Flu Emergency Response**: - Slug: `cdc-ends-h5n1-bird-flu-emergency-response` (new note) - Let's write a new note about the CDC deactivating its emergency response to the H5N1 bird flu outbreak, shifting human tracking to monthly seasonal influenza monitoring, and halting the publication of animal transmission data. - We will cite the MSN article we fetched. - Let's extract verbatim quotes: - From MSN: "The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move that removes a key policy tailwind for vaccine developers, including Moderna, Novavax, CureVac, and Traws Pharma." - From MSN: "The CDC reportedly deactivated its response last week and will now track bird flu alongside seasonal influenza, updating human monitoring data monthly... Animal transmission data will no longer be published, the agency said." - Let's write the note body. Let's double-check if we can resolve any threads. We have thread `019ec855-c507-7a87-9478-04ec177c54da` (FDA regulatory decision on Zepzelca's second-line SCLC indication). The trigger is: "Fires when the FDA or Jazz announces a regulatory decision, label update, or withdrawal of the second-line SCLC indication for Zepzelca." Since the FDA hasn't made a final decision or label update/withdrawal yet, we shouldn't resolve the thread, but we can write a note about the trial failure and keep the watch open. Wait, what about the other watches? - `019ec855-8c35-71a4-b33b-90db344bf45d` (FDA filing acceptance and PDUFA date for Belite Bio's tinlarebant). The trigger is: "Fires when the FDA decides whether to accept the NDA for filing (expected around early August 2026, 60 days post-submission)." Since the submission was completed on June 12, 2026, the 60-day review has just started. The watch is still open. - `019ec855-5381-7936-a3b6-a40d207e679d` (Amgen Tavneos FDA hearing submission and public docket close). The trigger is: "Fires when Amgen submits its evidence and the public docket closes on June 29, 2026." This is still in the future (June 29), so the watch is still open. - `019e9f1e-b37e-771d-884b-b07383d792b7` (sBLA submission for Zynlonta plus rituximab in r/r DLBCL). The trigger is: "ADC Therapeutics / FDA" (planned sBLA submission in Q4 2026). This is still in the future, so the watch is still open. - `019ec32d-357a-793f-b934-70957f5a30f5` (Sanofi Tzield Phase 3 BETA-PRESERVE confirmatory trial in Stage 3 T1D). The trigger is: "Fires when Sanofi reports topline safety and efficacy results from the Phase 3 BETA-PRESERVE trial." This is expected in 2028, so it is still open. This is perfect! We will update the notes to make sure they are accurate and comprehensive. Let's write the notes now. First, let's write `zepzelca-phase3-lagoon-sclc-failure`.I will update the existing note on Zepzelca's Phase 3 LAGOON failure to include the definitive trial outcome and data points announced on June 12, 2026.

Now, let's write the updated note for `amgen-tavneos-fda-scrutiny-withdrawal-dispute`.I will update the existing note on Amgen's Tavneos regulatory dispute to document their formal hearing request and selection of the Duke Clinical Research Institute (DCRI) to lead the independent data re-evaluation.

Now let's update the `sanofi-tzield-type1-diabetes` note with the newly approved pediatric Stage 3 T1D indication and the dramatic internal CDER battle.I will update the existing note on Sanofi's Tzield to document its newly granted accelerated approval for pediatric Stage 3 Type 1 Diabetes and the dramatic internal FDA controversy that preceded it.

Now let's update the `belite-bio-tinlarebant-stargardt-disease-nda` note with the completed rolling NDA submission.I will update the existing note on Belite Bio's tinlarebant to document the completion of its rolling NDA submission to the FDA on June 12, 2026.

Now let's update the `zynlonta-phase3-lotis5-dlbcl-safety-concerns` note with the detailed LOTIS-5 trial results.I will update the existing note on ADC Therapeutics' Zynlonta to document the detailed Phase 3 LOTIS-5 data, specifically the 13.2% vs 4.6% Grade 5 (fatal) TEAE imbalance, and the planned sBLA submission in Q4 2026.

Now let's write the new note for the CDC's deactivation of the H5N1 bird flu emergency response.I will write a new note documenting the CDC's deactivation of its H5N1 bird flu emergency response, transitioning to monthly tracking alongside seasonal influenza, and halting the publication of animal transmission data.

We have recorded all the updates and new notes! Let's see: Can we record some events for watches that have had major developments but aren't fully resolved yet? Wait, let's look at list_threads. - `019ec855-c507-7a87-9478-04ec177c54da` (FDA regulatory decision on Zepzelca's second-line SCLC indication). The trigger is: "Fires when the FDA or Jazz announces a regulatory decision, label update, or withdrawal of the second-line SCLC indication for Zepzelca." Since the FDA is still reviewing the failed LAGOON trial results, we should keep this watch open (resolves: false). Let's record an event on it to document the LAGOON trial failure! - `019ec855-5381-7936-a3b6-a40d207e679d` (Amgen Tavneos FDA hearing submission and public docket close). The trigger is: "Fires when Amgen submits its evidence and the public docket closes on June 29, 2026." Since it's June 15, 2026, the submission hasn't fully occurred yet, so this watch is still open. - `019e9f1e-b37e-771d-884b-b07383d792b7` (sBLA submission for Zynlonta plus rituximab in r/r DLBCL). The trigger is: "ADC Therapeutics / FDA" (planned sBLA submission in Q4 2026). This is still in the future, so the watch is still open. - `019ec855-8c35-71a4-b33b-90db344bf45d` (FDA filing acceptance and PDUFA date for Belite Bio's tinlarebant). The trigger is: "Fires when the FDA decides whether to accept the NDA for filing (expected around early August 2026, 60 days post-submission)." Since the submission was completed on June 12, 2026, the 60-day review has just started. The watch is still open. Let's record a watch event on the Zepzelca watch `019ec855-c507-7a87-9478-04ec177c54da` to show the LAGOON trial failed and the company has begun discussions with the FDA, keeping the watch open (`resolves: false`).I will record a watch event on Zepzelca's watch thread to document the Phase 3 LAGOON trial failure, keeping the watch open as we await the FDA's final regulatory action or label update.

This is perfect! We have completed all the necessary note-writing and watch-recording actions for this cycle. I will now call `finish_cycle` to conclude.

I have completed the research cycle for this topic. Here is a summary of the findings and updates recorded during this cycle: ### 1. **Jazz and PharmaMar's Zepzelca Fails Phase 3 LAGOON Confirmatory Trial in Second-Line SCLC** * **Slug:** `zepzelca-phase3-lagoon-sclc-failure` (Updated Note) * **Summary:** On June 12, 2026, Jazz and PharmaMar announced that the Phase 3 LAGOON confirmatory trial for Zepzelca (lurbinectedin) in second-line small cell lung cancer (SCLC) failed to meet its primary endpoint of overall survival (OS). Zepzelca monotherapy performed worse than standard chemotherapy (median OS of 8.7 months vs. 10.7 months for control, HR representing a 19% higher risk of death). The Zepzelca-irinotecan combination showed a marginal, non-statistically significant 9.8% improvement in OS. This second confirmatory failure (following the prior Atlantis trial flop) puts Zepzelca's accelerated second-line indication in serious jeopardy. * **Watch Status:** The watch evaluating the FDA's regulatory decision or label update for Zepzelca's second-line indication (`019ec855-c507-7a87-9478-04ec177c54da`) remains **open/ongoing** as Jazz has begun discussions with the FDA regarding the trial results. ### 2. **Amgen Formally Requests FDA Hearing & Enlists DCRI to Defend Tavneos** * **Slug:** `amgen-tavneos-fda-scrutiny-withdrawal-dispute` (Updated Note) * **Summary:** Amgen submitted a formal request for an FDA hearing on June 1, 2026 (made public on June 11, 2026) to contest the FDA CDER's proposal to withdraw approval of Tavneos (avacopan) for ANCA-associated vasculitis. Amgen has commissioned the Duke Clinical Research Institute (DCRI) to conduct an independent, blinded re-evaluation of the pivotal Phase 3 ADVOCATE trial data to counter allegations of clinical trial manipulation. The formal submission and public docket comments are due by June 29, 2026. * **Watch Status:** The watch on Amgen's Tavneos submission and public docket close (`019ec855-5381-7936-a3b6-a40d207e679d`) remains **open** until the June 29, 2026 deadline. ### 3. **FDA Grants Accelerated Approval to Sanofi's Tzield for Pediatric Stage 3 Type 1 Diabetes** * **Slug:** `sanofi-tzield-type1-diabetes` (Updated Note) * **Summary:** On June 12, 2026, the FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) to delay the decline of endogenous insulin production in pediatric patients ages 8 to 17 years with newly diagnosed Stage 3 Type 1 Diabetes, based on Phase 3 PROTECT trial data. The approval follows a dramatic internal CDER controversy where former acting CDER director Tracy Beth Høeg opposed the approval, leading to Sanofi attempting to withdraw the drug from the CNPV voucher program. Following Høeg's firing in late May 2026, acting CDER director Michael Davis cleared the path for the accelerated approval. * **Watch Status:** The watch on the confirmatory Phase 3 BETA-PRESERVE trial (`019ec32d-357a-793f-b934-70957f5a30f5`) remains **open** with results expected in 2028. ### 4. **Belite Bio Completes Rolling NDA Submission for Tinlarebant in Stargardt Disease** * **Slug:** `belite-bio-tinlarebant-stargardt-disease-nda` (Updated Note) * **Summary:** On June 12, 2026, Belite Bio completed its rolling NDA submission to the FDA for tinlarebant (LBS-008), an oral once-daily therapy for Stargardt disease type 1. The submission has entered the 60-day filing review window, after which the FDA will decide whether to accept the NDA and assign a PDUFA target action date. * **Watch Status:** The watch on the FDA's filing acceptance and PDUFA date (`019ec855-8c35-71a4-b33b-90db344bf45d`) remains **open** with a decision expected in early August 2026. ### 5. **ADC Therapeutics' Zynlonta LOTIS-5 Safety Concerns and Planned Q4 sBLA** * **Slug:** `zynlonta-phase3-lotis5-dlbcl-safety-concerns` (Updated Note) * **Summary:** Topline results from the Phase 3 LOTIS-5 trial of Zynlonta plus rituximab in r/r DLBCL showed a statistically significant improvement in PFS (median PFS of 6.1 months vs. 4.7 months, HR = 0.73, p = 0.008) but revealed a stark 3-to-1 imbalance in fatal (Grade 5) adverse events (13.2% vs. 4.6% for control). Despite the safety signal and a 53% drop in stock price, ADC Therapeutics plans to conduct a pre-sBLA meeting in August 2026 and submit a supplemental BLA in Q4 2026. * **Watch Status:** The watch on the sBLA submission for Zynlonta (`019e9f1e-b37e-771d-884b-b07383d792b7`) remains **open**. ### 6. **CDC Ends Emergency Response to H5N1 Bird Flu Outbreak** * **Slug:** `cdc-ends-h5n1-bird-flu-emergency-response` (New Note) * **Summary:** In June 2026, the CDC deactivated its emergency response to the H5N1 bird flu outbreak. Human tracking will now transition to monthly monitoring alongside seasonal influenza, and the agency will no longer publish animal transmission data. Affected states like California and Washington are also scaling down surveillance, sparking criticism from public health experts who warn that reducing surveillance leaves the country vulnerable to undetected resurgence or mutations. * **Watch Status:** The watch on Moderna's Phase 3 mRNA-1018 bird flu vaccine trial (`019e9f1e-f092-7114-960b-1c3b5c994320`) remains **open**.